EnClear is creating novel, first-in-class therapeutics for neurodegenerative disease. This position is within R&D, leading Biology. The primary responsibility of the newly created position is to lead the development and integration of the proprietary EnClear method for targeting and destroying toxic and inflammatory proteins found in CSF. This position requires expertise in human disease biology, a proven track record in managing CRO’s, capability to execute, strong leadership skills and ability to understand, prioritize and direct key method development programs. This position will work closely with management, CRO’s, R&D, regulatory and the SAB to ultimately launch the EnClear Therapeutic System.

Responsible for:
- Identification, validation and development of methods for destroying toxic and inflammatory proteins related to neurological diseases
- Develop and execute overall DPR protein quantification strategy
- Finalization of a calibrated method for measuring DPR size and concentration
- Design and implementation of toxicity and potency small and large animal models
- Manage of CRO’s
- Manage Scientific Advisory Board as it relates to biology and method

Qualifications and Education Requirements
- Neuro sciences, biology, neurodegenerative disease. PhD, postdoctoral training, and 5-10 years’ experience in basic biology, genomics and/or pharmacology or a closely related discipline
- 1-5 years’ industrial experience using cell biological and biochemical technologies to drive drug discovery in a pharmaceutical / biotech setting
- Strong track record of execution leading target discovery and validation projects and external collaborations with external academic and biotech resources
- Excellent leadership, collaboration, communication, and organizational skills, and ability and desire to work as part of a team dedicated to innovation
• Deep knowledge of cellular and molecular biology and biochemistry and at least one human disease area, with a strong preference for ALS & PSP
• Strong record of achievement as reflected in peer-reviewed publications

<table>
<thead>
<tr>
<th>Reviewed By:</th>
<th>TBD</th>
<th>Date:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved By:</td>
<td>A. DePasqua</td>
<td>Date:</td>
<td>03/21/2019</td>
</tr>
<tr>
<td>Last Updated By:</td>
<td>A. DePasqua</td>
<td>Date/Time:</td>
<td>03/21/2019</td>
</tr>
</tbody>
</table>